Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Enters The Alzheimer’s Disease Race, Plans Filings For Five New Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

As Merck heads into a “patent cliff” year, highlights of its analyst meeting included updates on key Phase III drugs, growth in emerging markets, and unveiling of new programs in Alzheimer’s disease and diabetes.

You may also be interested in...



Lilly Ends Trial Of BACE Inhibitor For Alzheimer’s, But Says Class-Wide Safety Effect Unlikely

With the termination of a Phase II trial of LY2887621, Merck’s MK-8931 leads the race to become the first BACE inhibitor approved for Alzheimer’s, although four other companies have similar candidates in earlier stages of development. Lilly says it may continue to pursue BACE inhibition in Alzheimer’s.

Merck On Track To File Novel Sleep Aid Suvorexant In 2012

Merck announced its potential first-in-class dual orexin receptor antagonist suvorexant successfully completed a second Phase III trial, apparently without safety concerns that led Actelion/GlaxoSmithKline to drop their DORA almorexant a year ago on Phase III results.

Diabetes Franchise May Help Merck Offset Loss Of Singulair

The Januvia/Janumet franchise posted sales growth of 40% both in the fourth quarter and over the full year for Merck, while Isentress and Gardasil also posted strong growth rates.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073040

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel